{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:06:41Z","timestamp":1785528401482,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:00:00Z","timestamp":1415750400000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"University Medical Centre Utrecht"},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Catharijne Foundation Utrecht"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.jacc.2013.04.101","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T17:16:03Z","timestamp":1377105363000},"page":"1834-1841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication"],"prefix":"10.1016","volume":"62","author":[{"given":"Anton P.","family":"van de Woestijne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Ho","family":"Liem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.M.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Westerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.04.101_bib1","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.04.101_bib2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions\u2014The Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.04.101_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.04.101_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2362.2009.02155.x","article-title":"Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c","volume":"39","author":"Hajer","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacc.2013.04.101_bib5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.101_bib6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/01.CIR.0000012918.84068.43","article-title":"Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors","volume":"105","author":"Sacks","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.04.101_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.04.101_bib8","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/hrt.2011.225466","article-title":"High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention","volume":"97","author":"Seo","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2013.04.101_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.04.101_bib10","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(10)62131-9","article-title":"HDL cholesterol and residual risk of first cardiovascular events","volume":"376","author":"Saely","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.04.101_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.04.101_bib12","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","article-title":"Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial","volume":"97","author":"Sacks","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.04.101_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","article-title":"Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22","volume":"29","author":"Ray","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2013.04.101_bib14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jacc.2010.01.008","article-title":"High-density lipoprotein and coronary heart disease: current and future therapies","volume":"55","author":"Natarajan","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.04.101_bib15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"Luscher","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.04.101_bib16","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.101_bib17","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.101_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2 Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.04.101_bib19","unstructured":"HPS2-THRIVE Collaborative Group. Press release: Niacin causes serious unexpected side-effects, but no worthwhile benefits, for patients who are at increased risk of heart attacks and strokes. Available at: http:\/\/www.thrivestudy.org\/press_release.htm. Accessed March 20,\u00a02013."},{"key":"10.1016\/j.jacc.2013.04.101_bib20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1023\/A:1007621514757","article-title":"Second manifestations of ARTerial disease (SMART) study: rationale and design","volume":"15","author":"Simons","year":"1999","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jacc.2013.04.101_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clinbiochem.2004.03.008","article-title":"Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population","volume":"37","author":"Tremblay","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jacc.2013.04.101_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A\u00a0systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jacc.2013.04.101_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ecl.2008.11.007","article-title":"Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety","volume":"38","author":"Hou","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jacc.2013.04.101_bib24","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1185\/03007995.2011.571239","article-title":"Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis","volume":"27","author":"Mikhailidis","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2013.04.101_bib25","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.04.101_bib26","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.04.101_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2012.01.029","article-title":"The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction","volume":"163","author":"Duffy","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.04.101_bib28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.101_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.atherosclerosis.2009.08.026","article-title":"Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis","volume":"208","author":"Drexel","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2013.04.101_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jacc.2007.07.086","article-title":"Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol","volume":"51","author":"deGoma","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.04.101_bib31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.04.101_bib32","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.101_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5551\/jat.5405","article-title":"Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions","volume":"17","author":"Yamashita","year":"2010","journal-title":"J\u00a0Atheroscler Thromb"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713030830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713030830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:02:21Z","timestamp":1760014941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713030830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":33,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0735109713030830"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.04.101","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.04.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}